Clinical Trials Logo

Filter by:
NCT ID: NCT06287229 Not yet recruiting - Relapsed/Refractory Clinical Trials

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

Start date: August 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving brexucabtagene autoleucel to patients with relapsed/refractory or high-risk, newly diagnosed B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD can help to control the disease.

NCT ID: NCT06286774 Not yet recruiting - Insomnia Clinical Trials

Sleep as a Mechanism of Change in Alcohol Use

ReTRAIN
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This project aims to evaluate improvement of insomnia as a mechanism of improvement in alcohol use outcomes.

NCT ID: NCT06286670 Not yet recruiting - Articular Fractures Clinical Trials

Single Versus Dual Implant Fixation of Distal Femur Fractures

PRORP
Start date: July 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare two types of surgical fixation in patients with specific kinds of distal femur fractures. The main questions it aims to answer is which operation for distal femur fractures is better for efficient return to work and everyday activities.

NCT ID: NCT06286397 Not yet recruiting - Pilonidal Sinus Clinical Trials

Topical Anti-Androgens in Pilonidal Sinus Disease

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are: - Does clascoterone improve the severity of pilonidal disease as scored by a physician? - Does clascoterone improve patient symptoms due to pilonidal disease? - Does clascoterone improve the inflammation seen under the microscope in pilonidal disease removed at surgery Participants will apply clascoterone or a placebo cream to the diseased area for 3 months. They will be assessed every 4 weeks for disease severity assessed by a physician viewing patient photos and a symptom-based survey. Researchers will compare participants who received clascoterone treatment to those who received placebo.

NCT ID: NCT06286319 Not yet recruiting - Lung Diseases Clinical Trials

Cold Oxygen Lung Preservation and Ventilation With the "Angel Cooler"

Start date: April 2024
Phase: N/A
Study type: Interventional

The objective of this feasibility study is to evaluate continuous temperature monitoring, oxygen (O2) concentration and ventilation with positive end expiratory pressure (PEEP) to keep lungs cooled at 4-8 degrees Celsius, with continuous O2 concentration of 100% and inflated with a PEEP of 8-10 during the entire cold ischemic period.

NCT ID: NCT06285916 Not yet recruiting - Clinical trials for Postpartum Depression

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

NuMom
Start date: February 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine: - How well NORA520 is tolerated and what side effects it may cause - If NORA520 reduces depressive symptoms in subjects with severe PPD - The amount of NORA520 in the blood at various times after taking the study drug; this provides information that helps determine how often NORA520 should be taken - In a subset of subjects, the amount of NORA520 in breastmilk at various times after taking it to determine if and how much NORA520 can pass into breastmilk Participate in this study will be randomly assigned to one of 3 different groups. All subjects will take the study drug for 3 days.

NCT ID: NCT06285825 Not yet recruiting - Cytopenia Clinical Trials

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Start date: July 31, 2024
Phase: Early Phase 1
Study type: Interventional

To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.

NCT ID: NCT06285487 Not yet recruiting - Depression Clinical Trials

Depression in Youth Onset Type 2 Diabetes

Start date: February 2024
Phase: N/A
Study type: Interventional

The main purpose of this study is to compare a group-based interpersonal psychotherapy (IPT) program and a Type 2 Diabetes education program to determine if there are differences in depression levels, diabetes distress, and glycemic control in adolescents with Type 2 Diabetes.

NCT ID: NCT06285253 Not yet recruiting - Acute Liver Failure Clinical Trials

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.

NCT ID: NCT06285032 Not yet recruiting - Opioid Use Clinical Trials

Decreasing Loneliness to Optimize Pain Care

DLoop
Start date: June 2024
Phase: N/A
Study type: Interventional

Loneliness, which is the perceived feeling of insufficient personal relationships, is related to higher risk for inappropriate opioid use and opioid use disorders in patients who are taking opioids long-term. The study seeks to pilot test the evidence-based loneliness interventions of psychological therapy and social navigation in patients on chronic opioids treated in primary care practices to determine if reducing loneliness can lower opioid misuse.